Legal & General Group
ZNTL icon

Legal & General Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Legal & General Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,940
Closed -$7.83K – 3558
2025
Q1 		$7.83K Hold
4,940
– – ﹤0.01% 3219
2024
Q4 		$15K Hold
4,940
– – ﹤0.01% 3138
2024
Q3 		$18.2K Sell
4,940
-48,378
-91% -$176K ﹤0.01% 3085
2024
Q2 		$218K Sell
53,318
-3,485
-6% -$38.9K ﹤0.01% 2652
2024
Q1 		$895K Buy
56,803
+1,226
+2% +$16.9K ﹤0.01% 2230
2023
Q4 		$842K Sell
55,577
-186
-0.3% -$2.71K ﹤0.01% 2259
2023
Q3 		$1.12M Buy
55,763
+854
+2% +$21.7K ﹤0.01% 2149
2023
Q2 		$1.55M Buy
54,909
+15,638
+40% +$375K ﹤0.01% 2038
2023
Q1 		$675K Buy
39,271
+1,158
+3% +$23.5K ﹤0.01% 2247
2022
Q4 		$768K Buy
38,113
+393
+1% +$8.45K ﹤0.01% 2223
2022
Q3 		$817K Buy
37,720
+2,229
+6% +$61K ﹤0.01% 2207
2022
Q2 		$998K Buy
35,491
+9,791
+38% +$259K ﹤0.01% 2158
2022
Q1 		$1.19M Buy
25,700
+15,650
+156% +$844K ﹤0.01% 2187
2021
Q4 		$845K Buy
10,050
+1,262
+14% +$97.7K ﹤0.01% 2276
2021
Q3 		$585K Buy
8,788
+4,242
+93% +$245K ﹤0.01% 2379
2021
Q2 		$241K Buy
4,546
+355
+8% +$19K ﹤0.01% 2489
2021
Q1 		$182K Buy
4,191
+98
+2% +$4.22K ﹤0.01% 2473
2020
Q4 		$212K Buy
4,093
+2,728
+200% +$123K ﹤0.01% 2410
2020
Q3 		$45K Sell
1,365
-314
-19% -$11K ﹤0.01% 2730
2020
Q2 		$81K Buy
+1,679
New +$64.4K ﹤0.01% 2589

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Legal & General Group's ZNTL Position: Q2 2025 in Review

Legal & General Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 4,940 shares — an estimated $7.83K sold.

Legal & General Group first reported a position in ZNTL in Q2 2020 and held it in 20 quarters. The position peaked at $1.55M in Q2 2023. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Legal & General Group reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 4,940 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $7.83K.
  • Legal & General Group first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 20 quarters.
  • Legal & General Group's Zentalis Pharmaceuticals position peaked at $1.55M in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.